Novavax, SK bioscience expand agreement to manufacture COVID vaccine containing Omicron variant
Gaithersburg: Novavax, Inc has signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.
The companies signed an agreement for the technology transfer of Novavax' proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants including the Omicron BA.5 subvariant.
"Non-clinical data generated to date demonstrate that our COVID-19 vaccine offers broad immune responses including against circulating variants, such as Omicron BA.5," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We are accelerating our clinical program evaluating an Omicron BA.5 component to our vaccine and look forward to continuing to work with SK bioscience as an important manufacturing partner."
In addition, the companies have signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe. SK bioscience will begin work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023.
Currently, SK bioscience manufactures drug substance for the vaccine. Novavax and SK bioscience also have a collaboration and licensing agreement under which SK bioscience exclusively commercializes the Novavax COVID-19 vaccine in South Korea, and with Novavax, jointly commercializes the vaccine in Vietnam and Thailand.
Read also: Novavax COVID vaccine gets USFDA emergency use nod for 18 years and older
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.